RCM
CRNX icon

RA Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

RA Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-564,102
Closed -$7.96M – 88
2020
Q4 		$7.96M Sell
564,102
-1,764,596
-76% -$24.6M 0.11% 74
2020
Q3 		$36.5M Hold
2,328,698
– – 0.67% 39
2020
Q2 		$40.8M Buy
2,328,698
+367,489
+19% +$6.26M 0.8% 32
2020
Q1 		$28.8M Buy
1,961,209
+86,000
+5% +$1.76M 0.91% 30
2019
Q4 		$47M Hold
1,875,209
– – 1.43% 19
2019
Q3 		$28.2M Hold
1,875,209
– – 1.68% 17
2019
Q2 		$46.9M Hold
1,875,209
– – 2.52% 10
2019
Q1 		$42.7M Hold
1,875,209
– – 1.84% 15
2018
Q4 		$56.2M Buy
1,875,209
+174,192
+10% +$4.9M 3.27% 11
2018
Q3 		$48.7M Buy
+1,701,017
New +$50.5M 2.61% 15

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RA Capital Management's CRNX Position: Q1 2021 in Review

RA Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2021, closing a stake of 564,102 shares — an estimated $7.96M sold.

RA Capital Management first reported a position in CRNX in Q3 2018 and held it in 10 quarters. The position peaked at $56.2M in Q4 2018. 80 funds tracked by Wall St. Rank hold CRNX as of Q1 2021.

  • RA Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • RA Capital Management sold 564,102 Crinetics Pharmaceuticals shares in Q1 2021, an estimated $7.96M.
  • RA Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 10 quarters.
  • RA Capital Management's Crinetics Pharmaceuticals position peaked at $56.2M in Q4 2018.
  • 80 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2021.

Based on RA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.